News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
7,839 Results
Type
Article (103)
Company Profile (2)
Press Release (7734)
Section
Business (4988)
Deals (510)
Drug Development (490)
FDA (69)
Job Trends (250)
News (5688)
Policy (172)
Tag
Academia (2)
Alliances (182)
Alzheimer's disease (5)
Antibody-drug conjugate (ADC) (3)
Approvals (68)
Autoimmune disease (2)
Best Places to Work (235)
Biotechnology (2)
Bladder cancer (1)
Breast cancer (1)
Cancer (14)
Cardiovascular disease (1)
CAR-T (1)
Cell therapy (1)
Clinical research (471)
Collaboration (5)
Compensation (10)
Complete response letters (1)
COVID-19 (8)
CRISPR (1)
C-suite (3)
Data (59)
Depression (1)
Diabetes (2)
Diagnostics (93)
Digital health (2)
Drug discovery (1)
Earnings (5261)
Events (347)
Executive appointments (2)
FDA (145)
Fibrodysplasia Ossificans Progressiva (1)
Funding (3)
Gene editing (2)
Gene therapy (2)
GLP-1 (9)
Government (15)
Guidances (69)
Healthcare (218)
IgA nephropathy (1)
Immunology and inflammation (4)
Infectious disease (9)
Intellectual property (2)
IPO (442)
Job creations (20)
Labor market (1)
Layoffs (1)
Legal (20)
Lung cancer (5)
Lymphoma (1)
Manufacturing (2)
MASH (3)
Medical device (215)
Medtech (217)
Mergers & acquisitions (80)
Metabolic disorders (14)
Multiple sclerosis (1)
Neurodegenerative disease (2)
Neuroscience (10)
NextGen: Class of 2026 (46)
Non-profit (15)
Obesity (8)
Pain (1)
Patents (1)
Patient recruitment (2)
People (136)
Phase 1 (63)
Phase 2 (223)
Phase 3 (210)
Pipeline (232)
Postmarket research (21)
Preclinical (25)
Prostate cancer (1)
Radiopharmaceuticals (5)
Rare diseases (6)
Real estate (11)
Regulatory (151)
Research institute (6)
Series A (1)
Series B (1)
Spinal muscular atrophy (1)
Startups (10)
Vaccines (4)
Weight loss (2)
Date
Last 7 days (8)
Last 30 days (26)
Last 365 days (549)
2026 (28)
2025 (558)
2024 (668)
2023 (819)
2022 (784)
2021 (801)
2020 (620)
2019 (383)
2018 (368)
2017 (239)
2016 (161)
2015 (293)
2014 (191)
2013 (132)
2012 (186)
2011 (171)
2010 (202)
Location
Africa (2)
Arizona (1)
Asia (355)
Australia (19)
California (226)
Canada (53)
China (13)
Colorado (11)
Connecticut (6)
Delaware (3)
Europe (816)
Florida (42)
Georgia (8)
Illinois (8)
Indiana (31)
Japan (8)
Kansas (1)
Kentucky (2)
Louisiana (3)
Maine (3)
Maryland (34)
Massachusetts (129)
Michigan (12)
Minnesota (11)
Missouri (3)
Montana (1)
New Hampshire (7)
New Jersey (49)
New York (51)
North Carolina (20)
Northern California (125)
Ohio (5)
Pennsylvania (45)
South America (5)
Southern California (87)
Tennessee (2)
Texas (17)
United States (760)
Utah (16)
Virginia (1)
Washington State (22)
Wisconsin (3)
7,839 Results for "488".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus
December 23, 2025
·
1 min read
Press Releases
Data of InnoCare’s ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD
March 10, 2025
·
2 min read
Press Releases
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China
March 20, 2025
·
3 min read
Drug Development
InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
May 15, 2024
·
2 min read
Policy
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China
InnoCare Pharma announced the first psoriasis patient has been dosed in clinical trial of the Company’s TYK2 JH2 allosteric inhibitor ICP-488 in China.
July 4, 2023
·
2 min read
Press Releases
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients
October 9, 2024
·
4 min read
Press Releases
U.S. Multiomics Market Size to Reach USD 4.88 Billion by 2033
June 21, 2024
·
1 min read
Press Releases
U.S. Plasmid DNA Manufacturing Market Size to Reach USD 4.88 Bn by 2033
June 13, 2024
·
16 min read
Biomaterials Market on Hit USD 488.9 BN, Globally, by 2030 at 15.8% CAGR
According to Nova one advisor, the global Biomaterials market size is expected to hit around USD 488.9 billion by 2030 from valued at USD 135.8 billion in 2021 and growing at a CAGR of 15.8% from 2022 to 2030.
November 23, 2022
·
7 min read
Drug Development
Alume Biosciences Announces First Patient Dosed with ALM-488 in Phase 3 Pivotal Study in Patients Undergoing Head and Neck Surgery
Alume Biosciences, Inc, a leader in the field of nerve-targeted diagnostics and therapeutics, announced that the first patient has been dosed in a Phase 3 pivotal study of ALM-488.
August 23, 2022
·
2 min read
1 of 784
Next
